Steroid Treatment for Eosinophilic Esophagitis
Topical corticosteroids are the recommended first-line pharmacologic therapy for EoE, with budesonide orodispersible tablets showing the highest efficacy rates and topical steroids strongly preferred over systemic steroids. 1, 2
Primary Recommendation: Use Topical Steroids, Not Systemic
Topical glucocorticosteroids should be used rather than oral systemic steroids for EoE treatment 1. While both achieve similar histologic improvement, systemic steroids cause significantly more adverse effects (40% rate including weight gain and cushingoid features) compared to topical formulations (15% rate, mainly oral candidiasis) 1. The similar efficacy with dramatically better safety profile makes topical steroids the clear choice.
Specific Topical Steroid Regimens
Budesonide (Preferred Agent)
Budesonide orodispersible tablets (BOT) demonstrate the highest efficacy, achieving clinico-histologic remission rates up to 75% after 1 year 3. In real-world practice, BOT was the most effective formulation with an odds ratio of 18.9 for achieving remission 4.
Dosing for budesonide:
- Standard dose: 2 mg twice daily (4 mg/day total) 4
- Higher doses (4 mg twice daily) provide no additional benefit over 2 mg twice daily, with both achieving 72-80% clinico-histologic remission 4
- Oral viscous budesonide suspension is an alternative when tablets unavailable, though gel formulations show superior histologic remission (84% vs 59% for capsules) 5
Fluticasone Propionate (Alternative)
Fluticasone dosing:
- High-dose regimen: 880 μg twice daily shows superior cure rates 6
- Doses ≥0.8 mg/day achieve 65% clinico-histologic remission and are superior to lower doses 4
- Swallowed nasal drop suspension is the most commonly used formulation 4
For children: 110 μg/puff for age <10 years; 220 μg/puff for age 11-18 years, given as 2 puffs 4 times daily 1
Duration and Maintenance Therapy
Initial induction therapy: 8-12 weeks minimum before assessing histologic response 2
Maintenance therapy is strongly recommended after achieving remission 1, 2. Clinical and histologic relapse rates are high (approximately 45%) after steroid withdrawal 1. Long-term topical steroid use (median 6.5 years) is both effective and safe, with only rare serious complications: adrenal insufficiency (1%), osteopenia (1%), and esophageal candidiasis (4%) 7.
Critical Success Factors
Adherence is the strongest predictor of treatment success. Patients with excellent adherence achieve 64% histologic response versus significantly lower rates with poor adherence 7. Endoscopic severity scores correlate strongly with adherence (EREFS 1.7 vs 4.0 for excellent vs poor adherence, p<0.001) 7.
Formulation matters significantly. The delivery vehicle affects treatment efficacy independent of dose—budesonide gel achieves 84% histologic remission versus 59% for capsules at identical 3 mg twice daily dosing 5. Direct oral administration (oral viscous preparations) achieves better results than aerosolized swallowed routes due to longer mucosal contact time 6.
Common Pitfalls and Caveats
Steroid resistance occurs in 25-40% of patients 6. A subset shows <50% reduction in eosinophils (15% for gel, 32% for capsules) 5. These patients require alternative therapies rather than dose escalation.
Persistent dysphagia despite histologic remission may indicate fibrostenotic disease. Narrow caliber esophagus (<13 mm) requires endoscopic dilation in addition to anti-inflammatory therapy 6. Medical treatment with topical steroids reduces stricture development, and combining dilation with effective steroid therapy improves outcomes in patients with existing strictures 2.
Do not discontinue steroids after initial remission without a maintenance plan. The disease will recur in the majority of patients, potentially leading to progressive fibrosis and stricture formation 1, 2.
Monitoring Strategy
Repeat endoscopy with biopsy is required to assess treatment response after 8-12 weeks of therapy 2. If symptoms recur while on treatment, repeat endoscopy to obtain histology and assess for complications 2.
The evidence strongly supports topical steroids as highly effective with an acceptable safety profile for both induction and long-term maintenance therapy in EoE, with formulation selection and adherence being key determinants of success.